RC-106

Cat. No.:	HY-158197
CAS No.:	1346216-50-9
Molecular Formula:	$C_{26}H_{29}N$
Molecular Weight:	355.52
Target:	Sigma Receptor; Proteasome
Pathway:	Neuronal Signaling; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	RC-106 is a proteasome inhibitor (IC50: 35 μM) and Sigma receptor modulator with anticancer activity. RC-106 has antiproliferative activity against cancer cells including glioblastoma (GB) and multiple myeloma (MM)[1].
In Vitro	RC-106 (60 μM; 24 h) inhibits cancer cell activity[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay[1]

Cell Line:	U87-MG cells
Concentration:	40, 60 μM
Incubation Time:	24 h
Result:	Showed a moderate activity against U87-MG cells at 60 μM, reducing the cell viability to 34%.

REFERENCES

[1]. Listro R, et al. Exploring the RC-106 Chemical Space: Design and Synthesis of Novel (E)-1-(3-Arylbut-2-en-1-yl)-4-(Substituted) Piperazine Derivatives as Potential Anticancer Agents. Front Chem. 2020 Jun 30;8:495.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA